iZafe Group AB (”iZafe”) has entered into an agreement with Mangold Fondkommission AB (Mangold) as liquidity provider for the iZafe share on Nasdaq First North Growth Market. The purpose of the liquidity provider is to improve the liquidity of the share and decrease the spread between the ask and bid price. Mangold’s assignment commences on November 30, 2021.

In its assignment as liquidity provider, Mangold will facilitate trade in the iZafe share by continuously maintaining both ask and bid orders in the order book. The purpose is to ensure a more accurate share price, which leads to a more accurate company valuation and improves the trading volume of the share.

Stockholm, Sweden – iZafe Group AB (publ.) (NASDAQ First North: IZAFE B) – today November 29, releases its Q3 Interim Report.

Summary of financial performance
• Net sales for the quarter totaled SEK 38 thousand (701). Sales for the quarter comprised revenue related to Dosell sales.
• Operating income for the quarter totaled SEK -5,342 thousand (7,255). The comparative period included the non-recurring effect from the sale of iZafe AB. Excluding the sale of iZafe, operating profit for the comparative period amounted to SEK -6,745 thousand.
• Income after financial items for the quarter was SEK -6,183 thousand (7,103). Excluding the sale of iZafe, income after financial items for the comparative period amounted to SEK -6,897 thousand.
• Cash flow for the period was SEK -6,475 thousand (8,818). The positive cash flow for the comparative period was due to the proceeds received from the divestment of iZafe AB.
• Earnings per share for the quarter, basic and diluted, were SEK -0.2 (0.2).
• Equity per share at the end of the period was SEK 1.5 (1.1).
• The equity ratio at the end of the period was 62.3 percent (87.4).

Important events in the quarter
• iZafe decided to carry out a fully guaranteed rights issue of units amounting to approximately SEK 53 million. The rights issue is fully guaranteed.
• iZafe Group held a general meeting of the shareholders, resulting in a supplementary general meeting at which a majority of shareholders requested an alternative Board of Directors, which was voted through.
The consumer pilot project has been successfully completed, with the consumer version of the Dosell medication-dispensing robot found to be safe and easy to use. Following the development of the consumer version of Dosell in Sweden, this version will also be launched in Italy in 2021.
• iZafe Group has signed an agreement with Apoteket AB to introduce Dosell on the Swedish consumer market, exclusively through Apoteket AB’s channels. The agreement with Apoteket, and its unique market position as one of the leading suppliers of medication sachets on the Swedish market, creates a direct market of the more than 200,000 people who currently take medication using medication sachets from suppliers such as Apoteket.

Important events since the end of the quarter
• The consumer version of Dosell is being launched in Sweden on apoteket.se. Dosell is now available for everyone who regularly takes medication and wants to avoid medication errors through better medication management and treatment compliance to prevent harm.
• The final outcome of the rights issue of units, consisting of shares and series TO10 B share warrants, has been published. The rights issue has been fully subscribed, with approximately 43.6 percent subscribed for using unit rights, around 4.1 percent without the use of unit rights and approximately 52.3 percent subscribed for by issue guarantors.
• Deputy Chairman Göran Hermansson and CEO Anders Segerström together subscribed for a further 458,000 units in the ongoing rights issue of units, in addition to the initial subscription.
• iZafe Group has finalized most of its PCT patent application for the Dosell medication-dispensing robot in order to prepare for the international expansion, planned to be carried out after the ongoing rights issue. Patent applications have been made in those key markets where iZafe has identified significant demand for Dosell.
• Hepro AS has last issued a final approval of the new version of Dosell and has officially approved the pharmaceutical robot in its entirety for the Norwegian market.

Comment by the CEO
With several milestones achieved, we are now letting the medical dispenser Dosell capitalize through several different sales channels, on the established market potential that the digitalization of healthcare and the increased drug consumption costs.

The rights issue that we have now carried out has given us resources to enable the upscaling and globalization of iZafe Group AB. It will also enable future acquisitions and broadening of the service and product portfolio. With a strong liquidity, we can now also work more strategically and long-term in all our decisions.

During the third quarter, we focused on completing Dosell for the consumer market, which resulted in us being approved by Apoteket AB to jointly launch Europe's first medical dispenser for the consumer market in mid-October. It also became clear that we are joining Dutch Adyen with its reliable payment solutions in the Dosell app. We see this as an obvious seal of quality, and we are happy for the collaboration. Their customers include companies such as H&M, Spotify and Telia.

During the quarter, we also worked to ensure the software and Dosell's quality in more markets. The continuous work to comply with MDR (Medical Device Regulation) continues according to plan, which is a requirement to have the classification Dosell has in the form of medical device product class 1.

The consumer product platform is secured in several countries, where we now see great potential. We have begun to approach solutions to the challenges we have had, including the complexity of the sales process and the dependence on other players in product development. Dosell is a unique product that is the first of its kind on a completely new market. This means that we need to raise the awareness towards our target groups, which is one of our highest priorities during the last quarter of the year. In November, we decided to accelerate our marketing efforts with the guidance of our new CMO and expect that this will have a major effect on sales figures during the last quarter of this year, but especially during the first quarter of 2022.
On the B2B side, several of our partners have chosen to test and secure Dosell 2.0 to ensure quality for their customers, which we view positively. However, this has led to longer lead times than we initially expected, which also had consequences for sales, which we can now begin. The tests have led to good response, results and market demand. The tests have also given us extremely important insights about our users, which further helped us to optimize the customer experience. In connection with Hepro now giving its approval for the new Dosellen, sales will also begin properly in the large Norwegian procurement that we won together last year. The collection of that data, both historically and in the future, will be important for us to provide the best and simplest support to ensure that the right medicine is taken at the right time. It is of the utmost importance that we have achieved approval and then "proof of concept" in our domestic market in order to be able to scale up in other markets in large volumes.
 
We focus on the future and are constantly exploring new expansion opportunities, both geographical and product-related, and see good potential in both areas.
We have also begun work on initiating several different future acquisitions, both on the product and company side, and we will focus on selected areas where we see a clear business potential with favorable synergy effects. We continue to work towards becoming the obvious choice when it comes to safe intake of the right medicine at the right time. Dosell that delivers medicine via sachet will be part of the customer offering where we will in future be able to supplement so we can ensure that the right medicine is taken at the right time also to users who take their medicine in other ways. In this sense, we believe that there are companies which can complement iZafe Group's portfolio in an advantageous way.

Basis for further growth
iZafe Group is a well-capitalized company operating in a rapidly growing market. Through the rights issue, we have created opportunities we have not had before. This is a crucial point to enable sales and the obvious choice in ensuring the right medicine at the right time.
We continue to work purposefully to strengthen our team, also at management level. Our latest addition is Carl-Fredrik Bothén, who has held senior positions in the market at several international companies. As marketing manager, Carl-Fredrik will be responsible for IR (Investor Relations) and for improving communication and driving and developing our marketing with a special focus initially on the Scandinavian market.
 
iZafe Group is well equipped to advance its positions during 2022. We are leaving behind an important quarter where many milestones have been achieved and with a market that shows great confidence in our product. I look forward to a strong end to 2021 and an even stronger 2022.

Hepro AS has last issued a final approval of the new version of Dosell and has officially approved the pharmaceutical robot in its entirety for the Norwegian market.

“We are pleased that all of our tests on the new Dosell have now been successfully completed and look forward to officially presenting the new improved Dosell to all Norwegian municipalities from now on. In the future, the pharmaceutical robot will be a priority product in Hepro's product portfolio. We can now finally start selling, which we look forward to.” Says Geir Tore Jakobsen CEO, Hepro AS

As Dosell is a medical technology product that requires high security and functionality, all of our partners have had to carry out their own internal controls of hardware and software and ensure all integrations and alarm handling. Following the implementation of the first version of Dosell, some technical challenges arose. The problems caused by the challenges have meant that the requirements for testing and quality assurance have become very high in order for the product to be approved. Dosell has now received this quality stamp and now that Hepro has given its approval, the pharmaceutical robot is now approved for the Scandinavian market.

"These tests have taken longer than the forecast. At the same time, we are very happy to work with such serious partners who make solid own checks to ensure all parts. Hepro AS has been a very important partner for us in the development and testing of Dosell 2.0 and it feels fantastic that the product is now secured at all levels.” Says Anders Segerström, CEO of iZafe Group AB.

Stockholm, Sweden, iZafe Group AB (publ) ("iZafe" or "the Company") announces the opportunity for shareholders, media, and other stakeholders to ask company-related questions in connection with its third quarter report. The report will be available to the public on November 29, 2021 at 08:30 (8:30 a.m.) CET.

Questions will be answered by Chief Executive Officer Anders Segerström and published on December 8, 2021 on iZafe Group's investor site under the heading Financial Reports, Investor Questions.
 
Please send your questions to before 10:00 (10 a.m.) CET on December 1, 2021.

Stockholm, Sweden, iZafe Group AB (publ) ("iZafe" or "the Company") today announced the appointment of Carl-Fredrik Bothén as Chief Marketing Officer. In his new role, Bothén will be an integral part of the executive team as he oversees the development and execution of iZafe marketing initiatives.

Carl-Fredrik has more than 25 years of experience in marketing, communication and digitalization. Among other things, he has worked as Nordic marketing manager for TP-Link Nordic AB and as marketing manager for Sixt rent a car. Carl-Fredrik also has experience from working in growth companies in various stages of development with a focus on, among other things, strategy work and growth. He will also place great emphasis on the Company's IR strategy and in connection with this will also be the contact person for shareholders and investors.

– In our growth journey, it has become natural to create a new position and bring in a senior CMO in the company. With Carl-Fredrik's solid experience in marketing and strategic experience of structured and long-term branding, I am convinced that he will be an important asset in our continued growth journey and management team, says Anders Segerström, CEO of iZafe Group AB.

“With many years of experience working with marketing communication, strategic planning and business development at internationally established companies, I can add expertise to iZafe Group by further developing the business to become a for-profit company. I have at an early stage formed a clear perception of our current situation and see a great potential to together with a very committed organization. I will be able to help increase our brand awareness and demonstrate sales figures, short-term and long-term”, says Carl-Fredrik Bothén, CMO at iZafe Group AB.

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED KINGDOM, THE UNITED STATES, CANADA, JAPAN, AUSTRALIA, HONG KONG, NEW ZEALAND, SWITZERLAND, SOUTH AFRICA OR ANY OTHER JURISDICTION WHERE SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL OR WOULD REQUIRE REGISTRATION OR ANY OTHER MEASURES .

iZafe Group AB (publ) ("iZafe" or the "Company") has completed the rights issue of units, consisting of shares and warrants of series TO10 B, resolved upon by the Board of Directors on September 6, 2021 (the "Rights Issue"). The Rights Issue has been subscribed for to a total of 100 percent, where approximately 43.6 percent was subscribed for by use of units rights, approximately 4.1 percent was subscribed for without use of units rights and approximately 52.3 percent was subscribed for by underwriters. The over-allotment issue described in the prospectus that was published on September 24, 2021, will not be carried out.

The subscription period in the Rights Issue ended on October 18, 2021. The final outcome shows that a total of 35,435,674 units have been subscribed for through the Rights Issue and the Company will thus receive approximately SEK 53.2 million before issue costs. Upon full exercise of all warrants of series TO10 B, the Company may be provided with an additional capital injection of up to approximately SEK 80 million after the exercise period that runs from and including September 27, 2022 to and including October 11, 2022.

Allocation of units subscribed for without the support of unit rights has taken place in accordance with what is stated in the prospectus that the Company published on September 24, 2021 due to the Rights Issue (the "Prospectus"). Notification of such allocation is announced separately by a settlement note sent out. Nominee-registered shareholders receive notification of allotment in accordance with instructions from the respective nominee.

Through the Rights Issue, the number of shares in the Company increase by 35,435,674 shares, from 35,435,674 shares to 70,871,348 shares and the share capital increase by SEK 35,435,674, from SEK 35,435,674 to SEK 70,871,348. In the event that all warrants are also fully exercised for subscription of new shares in the Company, the number of shares in the Company will increase with an additional maximum of 35,435,674 shares, from 70,871,348 shares to 106,307,022 shares, and the share capital will increase with an additional maximum SEK 35,435,674, from SEK 70,871,348 to SEK 106,307,022. Each warrant of series TO10 B entitles the holder to subscribe for one (1) new share in the Company at an exercise price corresponding to seventy (70) percent of the volume-weighted average price of the Company's share on Nasdaq First North Premier Growth Market during the period from and including September 12, 2022 to and including September 23, 2022, however a minimum of SEK 1.00 and a maximum of SEK 2.25 per share.

The Extraordinary General Meeting on September 23, 2021, resolved to authorize the Board of Directors to resolve on the over-allotment issue described in the prospectus that was published on September 24, 2021, in order to satisfy any oversubscription in the Rights Issue. However, the outcome in the Rights Issue means that the over-allotment issue will not be carried out.

Trading with BTU (Paid Subscribed Unit) takes place on Nasdaq First North Premier Growth Market until the conversion of BTU into shares and warrants after the Rights Issue has been registered with the Swedish Companies Registration Office. Registration with the Swedish Companies Registration Office is expected to take place during week 43, 2021.

In connection with the Rights Issue, a number of external investors have made underwriting commitments. For underwriting commitments made, underwriting compensation of 10 percent of the underwritten amount is paid in cash or alternatively 12 percent of the underwritten amount in the form of newly issued shares in the Company. Underwriters who wish to receive underwriting compensation in the form of newly issued shares must notify Mangold Fondkommission AB no later than 25 October, 2021. The subscription price for shares issued as underwriting compensation has been set at SEK 1.50 per share. In total, a maximum of 3,501,700 new shares may be issued as underwriters compensation to the underwriters.

Advisors
Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.

Important information
Release, announcement or distribution of this press release may, in certain jurisdictions, be subject to restrictions according to law and people in those jurisdictions, in which this press release has been announced or distributed, should inform themselves of and follow such legal restrictions. This press release does not constitute an offer, or a solicitation of any offer, to buy or subscribe for any securities in iZafe in any jurisdiction. Invitation to the persons concerned to participate in the Rights Issue has only taken place through the EU growth prospectus which the Company published on September 24, 2021.

This press release does not constitute or form part of an offer or solicitation to purchase or subscribe for securities in the United States. The securities referred to herein may not be sold in the United States absent registration or an exemption from registration under the US Securities Act of 1933, as amended. The information in this press release may not be announced, published or distributed in or into the United Kingdom, the United States, Canada, Japan, Australia, Hong Kong, New Zealand, Switzerland, South Africa or in any other jurisdiction where the announcement, publication or distribution of the information would not comply with applicable laws and regulations.

Within the European Economic Area, no offer is made to the public of securities in any country other
than Sweden. In other Member States of the European Union, such an offer may only be made in
accordance with the exceptions in the Prospectus Regulation (EU) 2017/1129.

This press release contains certain forward-looking information that reflects the Company’s present view of future events as well as financial and operational development. Words such as “intend”, “assess”, “expect”, “may”, “plan”, “believe”, “estimate” and other expressions entailing indications or predictions of future development or trends, not based on historical facts, constitute forward-looking information. Forward-looking information is inherently associated with both known and unknown risks and uncertainties as it depends on future events and circumstances. Forward-looking information is not a guarantee of future results or development and actual outcomes may differ materially from the statements set forth in the forward-looking information.

iZafe Group AB (publ.) (”iZafe” or ”the Company”) announces that the price for the consumer version of Dosell will be SEK 299 per month.

Dosell Consumer is a subscription service without binding period or notice period. A subscription for Dosell Consumer can be subscribed and paid for by, for example, the user directly or relatives to the user. After the customer has purchased the hardware for SEK 499 on apoteket.se, the service offers easy registration with payment solutions directly in the app.

”We are very happy that Dosell, as of Monday October 18, will be made available through apoteket.se for anyone to buy, to a relative or to themself. In an early stage we already have about 20 satisfied users that have tested Dosell before launch. We have visited some of them to hear more about how their everyday life has been made simpler and how their safe use of medication has been facilitated by the help of Dosell. See this video where two of our users and their families describe their experiences. Dosell Consumer is a welcome aid in the home for all people who medicate daily.” says Anders Segerström, CEO of iZafe.

About Dosell Consumer
Dosell Consumer and the Dosell app is a simpler version of iZafe´s professional solution and is adjusted to let users and relatives administrate and ensure correct medication without being dependent on healthcare staff. Both versions of the product are compatible with sachets from every supplier on the market.
 
Dosell Consumer will be made available for delivery by Apoteket on Monday October 18, 2021, but it is already possible to register interest to ensure availability when Dosell Consumer is launched.

iZafe Group AB (publ.) (“iZafe” or “the Company”) announces the initiation of the launch of Dosell Consumer as an end product to the healthcare service Sempli Farma. Today, 25 pharmacies in Italy have already subscribed to the service and are marketing it continuously – however, Sempli Farma has greater ambitions and are optimistic regarding the prospects of involving at least 150 Italian pharmacies in the first phase of the commercialization.

Every patient that is currently subscribed to Sempli Farma through the current 25 active pharmacies will be offered Dosell by the end of the year. Thus, the Company is optimistic towards the opportunity to begin sales to end-customers in Italy by the end of the year.

“The coming launch of the consumer version in Sweden has provided us with valuable insights towards planning a successful breakthrough in Italy as well. Our expectations for the Italian market are great leading into 2022. It is very positive that Dosell will be able to make use of tax reliefs in conjunction with purchases of digital systems in Italy. This leads the way for a quick and scale-able commercialization in Italy in parallel to Sweden” says Anders Segerström, CEO of iZafe Group.

iZafe has prepared robots in preparation of several pilot studies with Dosell in Italy. After a couple of months of use, Sempli Farma will gather interviews and film reference videos which will be used in communication and be made available through the sales network.

“The market has received the launch of Sempli Farma well and our marketing campaign, where Dosell is presented as the final component, has had a great effect. Dosell is unique on the market and completes our range of services to facilitate safe medication. During the latest nine months we have been contacted by all of the large actors in the healthcare sector (pharmacies and other healthcare networks) and we are currently in many negotiations. We want to believe that we have been a big part of making pharmacies and other stakeholders aware of the importance of dose-packaged medicine in order to facilitate correct medication and strengthen the public health.” says Alessandro Iadecola, CEO of Remedio S.R.L and Sempli Farma.

During the first quarter of 2022, Sempli Farma will begin integrated sales activities and commercialization of Dosell. In connection to this, the product will be offered to the patients that already subscribe to the service Sempli Farma through the 25 connected pharmacies. With the estimated 150 pharmacies that will be added in the next phase, a strong foundation will have been laid for the launch in Italy. A successful start of sales implies that iZafe can look ahead towards further international expansion in Spain and Portugal, which are the targetable markets that follow after Italy. Currently, there are no direct competitors to Dosell, either in Italy, Spain or Portugal.

About Sempli Farma by Remedio S.R.L
The Italian healthcare company Remedia has built a network of strategically chosen partners in Italy in order to find a combination of different medicine administration aids and distribution channels that enable elders to live at home for a longer period of time. In contrast to Sweden, the possibility to use sachets has not been available in Italy. This has inspired Remedio to launch this concept in Italy and develop the complete solution Sempli Farma.

Sempli Farma is a service that connects the treating doctor with the user and their relatives through a closed system of medical dispensing. The healthcare concept has a goal of reducing the cost of healthcare and making the Italian healthcare system more efficient. Dosell will be the ultimate component by delivering the sachets while simultaneously controlling medication and gathering statistics.

Sempli Farma has grown during 2020 and 2021 through a capital raise of EUR 300,000. The organization has gained strength with the addition of a clinical engineer, a sales manager that works to create an external sales network, as well as a marketing and communication department.

iZafe Group AB (publ) (”iZafe” or ”the Company”) announces that they have filed for several completions of their PCT patent application. Thus, the Company enables a greater geographic patent protection, which is part of iZafe’s strategy to strengthen and further develop its intangible assets internationally.

The scope of protection in question refers to the pharmaceutical robot Dosell and its services. The application has been submitted for protection in key markets that iZafe has identified and wherein iZafe has seen great demand for Dosell. These markets are Europe, the United States, Russia and China. The extensive geographic patent protection is sought in order to prepare for the international expansion that is planned to be executed after the ongoing rights issue.

“The pharmaceutical robot Dosell is perceived as simple and easy to use, both for the user and the caregiver, and this combined with an affordable price has led to us seeing a great potential internationally for both our corporate version and the consumer version. It is therefore crucial to work strategically with our intangible assets as we expand the business.” says Anders Segerström, CEO of iZafe Group.

Furthermore, the Company has filed an international patent application regarding advanced, digitalized and smart functions that provide a more intelligent and adaptable version of Dosell.

By using sensors and other digital care equipment in the home and regularly measuring patient-specific data, the system provides even safer medication for patients. The international patent application enables iZafe to obtain patents in more than 150 countries. The current patent application creates a strong basis for patent protection in selected markets, including Sweden, the whole of Europe, Asia and the United States.

iZafe Group AB (publ) (”iZafe” or ”the Company”) announces that Vice Chairman of the Board Göran Hermansson and CEO Anders Segerström are subscribing for an additional of combined 458,000 units in the ongoing rights issue of units (“ The Rights Issue”), which was announced and communicated through press release on September 6, 2021. An EU-growth prospect containing the full terms for the Rights Issue was announced and communicated through press release on September 24, 2021.

Today, the Company announces that Göran Hermansson and Anders Segerström will subscribe for a total of 458,000 units, corresponding to SEK 687,000.00 SEK. Göran Hermansson subscribes for 324,667 units, corresponding to SEK 487,000.50. Anders Segerström subscribes for 133,333 units, corresponding to SEK 199,999.50, in addition to his existing subscription commitment of SEK 315,046.50. Anders Segerström has received unit rights from Göran Hermansson in order to subscribe with preferential rights. This means that the Board of Directors and management have subscribed for a total of 876,149 units, corresponding to SEK 1,314,223.50 in the ongoing Rights Issue.

Subscription commitment and underwriting commitments
The Rights Issue is already covered to approximately 18 percent through subscription commitments and to approximately 82 percent through underwriting commitments. In total, 100 percent of the Rights Issue is thus covered by subscription commitments and underwriting commitments before Anders Segerström and Göran Hermansson’s additional subscriptions.

The subscription commitments have been made by a number of existing shareholders in the Company (by, among others, Chairman of the Board Joachim Källsholm, Board member Richard Wolff, CEO Anders Segerström, CFO Ida Almgren, Sales Manager Tobias Johansson, former Chairman of the Board Carl Johan Merner and the Company’s founders Göran Sjönell and Sten Röing) as well as external investors.

Important dates for the Rights Issue
Trading in unit rights on Nasdaq First North Premier Growth Market: October 4 – October 13, 2021
Subscription period for the Rights Issue: October 4 – October 18, 2021
Estimated date for publication of issue results: October 21, 2021

Advisors
Mangold Fondkommission AB is the financial advisor to iZafe in connection with the Rights Issue. Eversheds Sutherland Advokatbyrå AB is the legal advisor to the Company in connection with the Rights Issue.

Webbdesign av Comlog Webbyrå Stockholm